Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Molecular Partners
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
September 13, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
August 24, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
June 27, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 19, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
May 16, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
May 11, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
April 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
April 04, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2023
March 13, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
March 09, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
March 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
February 28, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
February 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
January 16, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
January 08, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
December 12, 2022
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
November 03, 2022
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
November 02, 2022
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
October 27, 2022
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Planned Departure of Chief Financial Officer
October 27, 2022
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.